

This is a free translation of the Adocia's table of financial resolutions issued in the French language, for informational purposes only.

DESCRIPTIVE TABLE ON THE FINANCIAL RESOLUTIONS TO BE SUBMITTED TO THE COMBINED SHAREHOLDERS' MEETING OF JUNE 11, 2025 (*)

The table below summarizes the key elements of each of the financial resolutions to be submitted to the combined Shareholders' Meeting of Adocia (the « **Company** ») to be held on June 11, 2025.

Resolution N°	Subject matter of the resolution	Description
16	Authorization to be given to the Board to reduce stated capital by cancelling shares pursuant to the authorization to purchase its own shares.	<ul style="list-style-type: none"> - Limitation of 10% of registered capital per 24 months. - Validity period: 18 months. - Delegation cannot be used during a public offer. - Renewal of the 16th resolution of the shareholders' meeting of June 13, 2024.
17	Delegation of authority to the Board of Directors to increase the Company's capital, immediately or in the future, by issuing ordinary shares and/or securities, with pre-emptive subscription rights for existing shareholders.	<ul style="list-style-type: none"> - Total amount of stated capital increases which can be decided under this resolution: € 940,000. - Maximum amount of debt securities giving access to registered capital that can be issued under this resolution: € 50,000,000. - Within the limit of the overall ceiling provided for in the 24th resolution. - Validity period: 26 months. - Renewal of the 16th resolution of the shareholders' meeting of June 13, 2024.
18	Delegation of authority to be granted to the Board to increase capital by issuing common shares and/or equity securities, without a preemptive subscription right for shareholders and offer to the public.	<ul style="list-style-type: none"> - Total amount of stated capital increases which can be decided under this resolution: € 360,000. - Maximum amount of debt securities giving access to registered capital that can be issued under this resolution: € 50,000,000. - Within the limit of the overall ceiling provided for in the 24th resolution. - Validity period: 26 months. - Renewal of the 18th resolution of the shareholders' meeting of June 13, 2024.

* See the text of resolutions for more details.

19	<p>Delegation of authority to be granted to the Board to increase capital by issuing common shares and/or equity securities without a preemptive subscription right for shareholders as part of an offering provided in paragraph I of Article L. 411-2 of the French Monetary and Financial Code and offer to the public.</p>	<ul style="list-style-type: none"> - Total nominal amount of the capital increases that may be decided pursuant to this resolution: € 360,000. - Maximum nominal amount of debt securities giving access to share capital that can be issued under this resolution: € 50,000,000. - Within the limit of the overall ceiling provided for in the 24th resolution. - Validity period: 26 months. - Issue price fixed by the Board and at least equal to the weighted average of the last three trading days, minus a legal maximum discount (i.e. 20%). - Delegation cannot be used during a public offer. - Renewal of the 19th resolution of the shareholders' meeting of June 13, 2024.
20	<p>Delegation of authority to the Board of Directors to increase the Company's capital, up to a maximum of 30% of the capital, by issuing ordinary shares and/or any other securities without shareholders' pre-emptive subscription rights, to the benefit of persons designated by name - delegation to the Board of Directors of the power to designate such persons.</p>	<ul style="list-style-type: none"> - Total nominal amount of capital increases that may be carried out under this resolution: € 540,000. - Maximum nominal amount of debt securities giving access to share capital that can be issued under this resolution: € 50,000,000. - Subject to the overall ceiling set out in the 24th resolution. - Duration of delegation: 18 months. - Up to a maximum of 30% of the capital per 12-month period.
21	<p>Delegation of authority to be granted to the Board to increase capital immediately or in the future by issuing common shares and/or equity securities, without a preemptive subscription right for shareholders, for the benefit of a category of persons that satisfy specified characteristics (active investors in the sector health or biotechnologies).</p>	<ul style="list-style-type: none"> - Total nominal amount of the capital increases that may be decided pursuant to this resolution: € 540,000. - Maximum nominal amount of debt securities giving access to share capital that can be issued under this resolution: € 50,000,000. - Within the limit of the overall ceiling provided for in the 23th resolution. - Issue price fixed by the Board and at least equal to the weighted average of the last three trading days, minus a legal maximum discount (i.e. 20%). - Delegation cannot be used during a public offer. - Validity period: 18 months. - Renewal of the 21st resolution of the shareholders' meeting of June 13, 2024.

22	Delegation of authority to be granted to the Board to increase capital immediately or in the future by issuing common shares and/or equity securities, without a preemptive subscription right for shareholders, for the benefit of a category of persons that satisfy specified characteristics (strategic or financial partners).	<ul style="list-style-type: none"> - Total nominal amount of the capital increases that may be decided pursuant to this resolution: € 540,000. - Maximum nominal amount of debt securities giving access to share capital that can be issued under this resolution: € 50,000,000. - Within the limit of the overall ceiling provided for in the 24th resolution. - Issue price fixed by the Board and at least equal to the weighted average of the last three trading days, minus a legal maximum discount (i.e. 20%). - Delegation cannot be used during a public offer. - Validity period: 18 months. - Renewal of the 22nd resolution of the shareholders' meeting of June 13, 2024.
23	Delegation of authority granted to the Board of Directors to increase capital by issuing common shares with or without a preemptive subscription right for shareholders as decided in the above-mentioned resolutions.	<ul style="list-style-type: none"> - Possibility to increase by 15% the number of securities to be issued in the event of a capital increase with or without a preemptive subscription right for shareholders, within the limit of 15% of the initial increase under the above resolutions. - At the same price as the original issue and within the limit of 15% of the initial issue. - Within the limit of the overall ceiling provided for in the 24th resolution. - Validity period: 26 months. - Renewal of the 23rd resolution of the shareholders' meeting of June 13, 2024.
24	Aggregate limits on the issues completed pursuant to the resolutions above.	<ul style="list-style-type: none"> - Total nominal amount of capital increases that may be decided pursuant to this resolution: € 940,000. - Maximum nominal amount of debt securities giving access to share capital that can be issued under this resolution: € 50,000,000. - Renewal of the 26th resolution of the shareholders' meeting of June 13, 2024.

25	<p>Delegation of authority to the Board of Directors to increase the Company's capital by issuing ordinary shares and/or other securities, without pre-emptive subscription rights for existing shareholders, for the benefit of a category of persons meeting specified criteria within the scope of an equity or bond financing agreement.</p>	<ul style="list-style-type: none"> - Total nominal amount of the capital increases that may be decided pursuant to this resolution: € 360,000. - Maximum nominal amount of debt securities giving access to share capital that can be issued under this resolution: € 50,000,000. - Issue price fixed by the Board and at least equal to the weighted average of the last three trading days, minus a legal maximum discount (i.e. 20%). - Ceiling set separately from the ceiling referred to in the 24th resolution. - Delegation cannot be used during a public offer. - Validity period: 18 months. - Renewal of the 27th resolution of the shareholders' meeting of June 13, 2024.
26	<p>Authorization for the Board of Directors to grant options to subscribe for or purchase shares in the Company, in accordance with the provisions of Articles L. 225-177 et seq. of the French Commercial Code, waiving shareholders' pre-emptive subscription rights.</p>	<ul style="list-style-type: none"> - Maximum number of shares that may be issued on exercise of options: 325,000. - The purchase or subscription price per share may not be (i) less than 95% of the average share price quoted over the twenty trading days preceding the date of the Board's decision to grant the options, rounded down to the nearest euro, nor, in the case of stock purchase options, (ii) less than 80% of the average purchase price of treasury shares held by the Company, rounded down to the nearest euro. - Options valid for 10 years. - Subject to the overall ceiling set out in the 29th resolution. - Validity period: 38 months. - Renewal of the 25th resolution of the shareholders' meeting of June 13, 2024.
27	<p>Authorization for the Board of Directors to grant existing shares or shares to be issued without consideration, in accordance with the provisions of Articles L. 225-197-1 et seq. of the French Commercial Code, with shareholders waiving their pre-emptive subscription rights.</p>	<ul style="list-style-type: none"> - Maximum number of shares that may be issued on exercise of options: 500,000. - Vesting period of at least 1 year and cumulative vesting and holding period of at least 2 years. - Options valid for 10 years. - Within the overall limit set in the 29th resolution. - Term of delegation: 38 months. - Renewal of the 31st resolution of the Annual General Meeting of June 13, 2024.

28	<p>Delegation of authority to the Board of Directors to issue and grant stock warrants without pre-emptive subscription rights to (i) members and non-voting members of the Company's Board of Directors in office at the date of grant of the warrants, (ii) persons bound to the Company or one of its subsidiaries by a service or consultancy contract, or (iii) members of any committee that the Board of Directors has set up or may set up in the future.</p>	<ul style="list-style-type: none"> - The issue price of a warrant will be determined by the Board on the day of issue of the said warrant based on the characteristics of the warrant and will be at least equal to 15% of the volume-weighted average price of the last five (5) trading days. - Maximum number of shares that can be issued upon exercise of BSA: 325,000. - Subscription price of the share to which the BSA gives right must at least be equal to the highest value between (i) sale price of a share the day before the allocation, and (ii) the weighted average of the 20 trading sessions. - Validity of the BSA: 10 years. - Subject to the overall ceiling set out in the 29th resolution. - Validity period: 18 months. - Renewal of the 30th resolution of the shareholders' meeting of June 13, 2024.
29	<p>Overall limits on the amount of issues carried out pursuant to the twenty-sixth, twenty-seventh and twenty-eighth resolutions above.</p>	<ul style="list-style-type: none"> - Total number of shares that may be issued under the 26th, 27th and 28th resolutions may not exceed 900,000 shares. - Renewal of the 32nd resolution of the shareholders' meeting of June 13, 2024.
30	<p>Delegation of authority to the Board of Directors to increase share capital by capitalizing additional paid-in capital, reserves, profits or other items</p>	<ul style="list-style-type: none"> - Total nominal amount of capital increases that may be carried out under this resolution: € 100,000. - This ceiling is set independently and separately from the ceiling specified in the 24th resolution. - Duration of the authorization: 26 months. - Renewal of the 30th resolution of the Annual General Meeting of May 11, 2023.

31	Delegation to be granted to the Board to increase stated capital by issuing shares without a preemptive subscription right for shareholders in favor of the employees who participate in a corporate savings plan.	<ul style="list-style-type: none"> - Capital increase reserved for employees who are members of a PEE of the company. - Total nominal amount of the capital increases that may be decided pursuant to this resolution: € 20,000. - The issue price of shares giving access to capital will be determined by the board of directors and may not be higher than the average of the prices quoted at the 20 trading sessions preceding the day of the decision of the board of directors fixing the date subscription opening period or more than 20% below this average or 30% when the unavailability period provided for by the plan is greater than or equal to 10 years. - Validity period: 18 months. - Renewal of the 30th resolution of the shareholders' meeting of June 13, 2024.
32	Modification of the article 12 of the bylaws.	<ul style="list-style-type: none"> - The Attractiveness Act introduced the following options for Board decisions: - Public right to participate by means of telecommunication (no need for a clause to this effect in the by-laws), except for decisions listed exhaustively in the by-laws or by-laws. - Possibility of participating by telecommunication in all decisions (previously prohibited for the preparation of the inventory, annual financial statements, management report, consolidated financial statements and group management report). - Generalization of written consultation, by electronic means if necessary, subject to the right of objection of any Board member. - Admission of postal voting.